Curcumin has bright prospects for the treatment of multiple sclerosis

被引:84
|
作者
Xie, Lin [2 ]
Li, Xiao-Kang [1 ]
Takahara, Shiro [2 ]
机构
[1] Natl Res Inst Child Hlth & Dev, Div Radiat Safety & Immune Tolerance, Setagaya Ku, Tokyo 1578535, Japan
[2] Osaka Univ, Grad Sch Med, Dept Adv Technol Transplantat, Osaka, Japan
关键词
Autoimmune disease; Curcumin; Multiple sclerosis; Experimental autoimmune encephalomyelitis; Th17; cells; Interleukin-17; NF-kappa B; Chemokine; Cytokine; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BLOOD-BRAIN-BARRIER; FACTOR-KAPPA-B; CHEMOPREVENTIVE AGENT CURCUMIN; OXIDE SYNTHASE ACTIVATION; ENTEROBACTERIA LEAKY GUT; NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; I CLINICAL-TRIAL; TH17; CELLS;
D O I
10.1016/j.intimp.2010.08.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS). It is associated with a variety of pathophysiological features, including breakdown of the blood-brain barrier (BBB), autoimmune attack, injury of axons and myelin sheaths. Th17 cells are considered as a key immunological player for the pathophysiological process of MS. Neuroprotective approaches work best prior to the initiation of damage, suggesting that some safe and effective prophylaxis would be highly desirable. Curcumin, a dietary spice from turmeric, has outstanding anti-inflammation and neuroprotective effects. Herein, we review key features of curcumin involved biology, pharmacology, and medicinal chemistry and discuss its potential relevance to pathophysiological progress of MS. (c) 2010 Elsevier B.V. All rights reserved.
引用
下载
收藏
页码:323 / 330
页数:8
相关论文
共 50 条
  • [41] Immunomodulatory medicines for multiple sclerosis: Progress and prospects
    Palmer, Alan M.
    DRUG DEVELOPMENT RESEARCH, 2011, 72 (08) : 664 - 673
  • [42] Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite
    Koprowski, H
    Spitsin, SV
    Hooper, DC
    ANNALS OF NEUROLOGY, 2001, 49 (01) : 139 - 139
  • [43] The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers
    Khademi, M.
    Bornsen, L.
    Rafatnia, F.
    Andersson, M.
    Brundin, L.
    Piehl, F.
    Sellebjerg, F.
    Olsson, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) : 528 - 536
  • [44] Multiple sclerosis has a highly divergent prognosis
    Skoog, B.
    Runmarker, B.
    Andersen, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 143 - 143
  • [45] Has leptin a role in immunoregulation of multiple sclerosis?
    Misso, S
    Feola, B
    Minerva, A
    Fratellanza, G
    Orefice, G
    Lombardi, E
    Di Lauro, A
    JOURNAL OF NEUROIMMUNOLOGY, 2004, 154 (1-2) : 214 - 214
  • [46] Has the pandemic changed treatment strategy in multiple sclerosis? Insights from an Austrian registry
    Bsteh, G.
    Riedl, K.
    Krajnc, N.
    Kornek, B.
    Leutmezer, F.
    Macher, S.
    Rommer, P.
    Zulehner, G.
    Berger, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 281 - 281
  • [47] Treatment of multiple sclerosis
    Bereznai, B
    Goebels, N
    Dang, T
    Voltz, R
    Walther, E
    Zimmermann, C
    Hohlfeld, R
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1999, 124 (19) : 595 - 599
  • [48] TREATMENT OF MULTIPLE SCLEROSIS
    WELTE, E
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1967, 92 (16) : 765 - &
  • [49] TREATMENT OF MULTIPLE SCLEROSIS
    MILLER, H
    PRACTITIONER, 1964, 192 (114) : 62 - &